These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30738488)

  • 1. [Recent Progress of Molecular Genetic Characteristics and Prognosis of Non-Hodgkin's Lymphoma--Review].
    Wang ZH; Xu M; Gu XL; Xu Z; Yu FY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):301-305. PubMed ID: 30738488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel epigenetic markers in non-Hodgkin's lymphoma.
    Shi H; Guo J; Duff DJ; Rahmatpanah F; Chitima-Matsiga R; Al-Kuhlani M; Taylor KH; Sjahputera O; Andreski M; Wooldridge JE; Caldwell CW
    Carcinogenesis; 2007 Jan; 28(1):60-70. PubMed ID: 16774933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-Hodgkin's lymphoma: the old and the new.
    Cabanillas F
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S87-90. PubMed ID: 22035756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chromosomal aberrations in non-Hodgkin's lymphoma. Biologic and clinical correlations.
    Offit K; Chaganti RS
    Hematol Oncol Clin North Am; 1991 Oct; 5(5):853-69. PubMed ID: 1938758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent Cytogenetic Abnormalities in Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia.
    Ma ES
    Methods Mol Biol; 2017; 1541():279-293. PubMed ID: 27910030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of chromosomal abnormalities in non-Hodgkin's lymphomas - review].
    Zhang L; Zhao XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun; 16(3):717-20. PubMed ID: 18549661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-Hodgkin lymphoma.
    Armitage JO; Gascoyne RD; Lunning MA; Cavalli F
    Lancet; 2017 Jul; 390(10091):298-310. PubMed ID: 28153383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epstein-Barr virus-associated extranodal non-Hodgkin's lymphoma of the sinonasal tract and nasopharynx in Thailand.
    Mitarnun W; Suwiwat S; Pradutkanchana J
    Asian Pac J Cancer Prev; 2006; 7(1):91-4. PubMed ID: 16629523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hodgkin's and non-Hodgkin's lymphoma of the head and neck.
    Urquhart A; Berg R
    Laryngoscope; 2001 Sep; 111(9):1565-9. PubMed ID: 11568605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-resolution loss of heterozygosity screening implicates PTPRJ as a potential tumor suppressor gene that affects susceptibility to Non-Hodgkin's lymphoma.
    Aya-Bonilla C; Green MR; Camilleri E; Benton M; Keane C; Marlton P; Lea R; Gandhi MK; Griffiths LR
    Genes Chromosomes Cancer; 2013 May; 52(5):467-79. PubMed ID: 23341091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Association of XRCC1 genetic polymorphism with susceptibility to non-Hodgkin's lymphoma].
    Li SX; Zhu HL; Guo B; Yang Y; Wang HY; Sun JF; Cao YB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):982-7. PubMed ID: 25130814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
    Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
    J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-Hodgkin's lymphoma: morphologic, immunologic and cytogenetic classification].
    Ristić S; Jovanović V; Ristić S; Radojković M
    Srp Arh Celok Lek; 1996; 124(9-10):276-82. PubMed ID: 9102863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [C-terminal 30 bp-deletion mutation of latent membrane protein 1 gene of Epstein-barr virus in non-hodgkin's lymphoma].
    Liu JR; Lin Q; Wu XY
    Ai Zheng; 2005 Feb; 24(2):145-8. PubMed ID: 15694022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?
    Josting A; Reiser M; Rueffer U; Salzberger B; Diehl V; Engert A
    J Clin Oncol; 2000 Jan; 18(2):332-9. PubMed ID: 10637247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin's disease.
    Kant JA; Hubbard SM; Longo DL; Simon RM; DeVita VT; Jaffe ES
    J Clin Oncol; 1986 Mar; 4(3):284-94. PubMed ID: 3754003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of TRIP6 promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR) via regulating nuclear p27(Kip1) expression in non-Hodgkin's lymphoma.
    Miao X; Xu X; Wu Y; Zhu X; Chen X; Li C; Lu X; Chen Y; Liu Y; Huang J; Wang Y; He S
    Tumour Biol; 2016 Jan; 37(1):1369-78. PubMed ID: 26298725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between Hodgkin's and non-Hodgkin's lymphomas.
    Amini RM; Enblad G
    Med Oncol; 2003; 20(3):211-20. PubMed ID: 14514970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single nucleotide polymorphism in 5'-flanking region of BCL6 is not associated with increased risk of non-Hodgkin's lymphoma.
    Susova S; Trneny M; Soucek P
    Cancer Lett; 2006 Jul; 238(1):142-5. PubMed ID: 16125304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities.
    Møller MB; Nielsen O; Pedersen NT
    Mod Pathol; 1999 Nov; 12(11):1010-6. PubMed ID: 10574597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.